Clélia Bardonneau

Oral fexinidazole for late-stage African Trypanosoma brucei gambiense trypanosomiasis: a pivotal multicentre, randomised, non-inferiority trial

Victor Kande Betu Ku Mesu, Wilfried Mutombo Kalonji, Clélia Bardonneau et al. · The Lancet · 2017 · 265 citations

Parasitic Protozoa, African Trypanosomiasis, Pathogenesis +6

A randomized trial of AmBisome monotherapy and AmBisome and miltefosine combination to treat visceral leishmaniasis in HIV co-infected patients in Ethiopia

Ermias Diro, Séverine Blesson, Tansy Edwards et al. · PLoS neglected tropical diseases · 2019 · 80 citations · Full text

Oral fexinidazole for stage 1 or early stage 2 African Trypanosoma brucei gambiense trypanosomiasis: a prospective, multicentre, open-label, cohort study

Victor Kande Betu Ku Mesu, Wilfried Mutombo Kalonji, Clélia Bardonneau et al. · The Lancet Global Health · 2021 · 55 citations · Full text

Long term outcomes and prognostics of visceral leishmaniasis in HIV infected patients with use of pentamidine as secondary prophylaxis based on CD4 level: a prospective cohort study in Ethiopia

Ermias Diro, Tansy Edwards, Koert Ritmeijer et al. · PLoS neglected tropical diseases · 2019 · 42 citations · Full text

Safety and efficacy of oral fexinidazole in children with gambiense human African trypanosomiasis: a multicentre, single-arm, open-label, phase 2–3 trial

Victor Kande Betu Kumesu, Wilfried Mutombo Kalonji, Clélia Bardonneau et al. · The Lancet Global Health · 2022 · 18 citations · Full text